BETRF — BetterLife Pharma Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1464165 ·
Last close
$0.22
Market Cap
$37.95M
52W High
$0.33
52W Low
$0.03
ADV30
106,628
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -561,395 | -609,257 | 242,428 | 28,576 | 6,676,796 |
| Jan 2026 | 0 | — | -437,008 | -380,547 | 219,903 | 12,570 | 6,706,283 |
| Oct 2025 | 0 | — | -389,215 | -409,014 | 291,127 | 7,962 | 6,456,866 |
| Jul 2025 | 0 | — | -511,630 | -494,476 | 229,340 | 22,163 | 6,040,439 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-850,443
Investing CF
—
Financing CF
$859,322
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.00
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-120,700,750
Inventory
—
Receivables
$7,974
ST Investments
—
EBIT TTM
$-1,733,854
Pretax Income TTM
$-1,918,486
Interest Exp TTM
$184,632
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jan 2026 | 0 | -1,808,600 | -1,495,492 | 219,903 | 6,706,283 | -9,784,058 | -625,455 |
| Jan 2025 | 0 | -4,724,931 | -3,520,288 | 224,963 | 7,587,112 | -10,677,529 | -2,021,752 |
| Jan 2024 | 0 | -3,209,889 | -2,889,032 | 324,746 | 8,020,513 | -10,808,521 | -2,472,410 |
| Jan 2023 | 0 | -9,257,441 | -9,016,201 | 74,727 | 7,608,197 | -10,728,221 | -1,503,512 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MIRA | MIRA PHARMACEUTICALS, INC. | $37.96M | $0.90 | — |
| NNVC | NANOVIRICIDES, INC. | $38.29M | $1.50 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $37.17M | $2.53 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $37.10M | $1.18 | — |
| KPTI | Karyopharm Therapeutics Inc. | $36.74M | $1.62 | — |
News headlines (Yahoo Finance, 1h cache)
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-09-17 14:41 · Yahoo
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-09-11 23:45 · Yahoo
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
2026-08-31 12:00 · Yahoo
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-08-28 12:00 · Yahoo
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
2026-08-24 22:42 · Yahoo
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
2026-07-13 12:00 · Yahoo
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
2026-06-25 12:00 · Yahoo
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
2026-05-13 12:00 · Yahoo
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
2026-08-19 12:00 · Yahoo
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
2026-07-06 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.